These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25936721)

  • 41. Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.
    Fortaleza CM; Freire MP; Filho Dde C; de Carvalho Ramos M
    Infect Control Hosp Epidemiol; 2006 Sep; 27(9):901-6. PubMed ID: 16941313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
    Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
    Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.
    Eagye KJ; Kuti JL; Sutherland CA; Christensen H; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2678-88. PubMed ID: 20110010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
    Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa.
    Gasink LB; Fishman NO; Nachamkin I; Bilker WB; Lautenbach E
    Infect Control Hosp Epidemiol; 2007 Oct; 28(10):1175-80. PubMed ID: 17828695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.
    Lautenbach E; Synnestvedt M; Weiner MG; Bilker WB; Vo L; Schein J; Kim M
    Infect Control Hosp Epidemiol; 2010 Jan; 31(1):47-53. PubMed ID: 19951202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
    Friedland I; Gallagher G; King T; Woods GL
    J Chemother; 2004 Oct; 16(5):437-41. PubMed ID: 15565908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
    Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
    Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control.
    Bonten MJ; Bergmans DC; Speijer H; Stobberingh EE
    Am J Respir Crit Care Med; 1999 Oct; 160(4):1212-9. PubMed ID: 10508809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000-2004.
    Messadi AA; Lamia T; Kamel B; Salima O; Monia M; Saida BR
    Burns; 2008 Dec; 34(8):1098-102. PubMed ID: 18619737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.
    Walkty A; Decorby M; Nichol K; Mulvey MR; Hoban D; Zhanel G;
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):217-21. PubMed ID: 18304774
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
    Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K
    New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit.
    Nseir S; Blazejewski C; Lubret R; Wallet F; Courcol R; Durocher A
    Clin Microbiol Infect; 2011 Aug; 17(8):1201-8. PubMed ID: 21054665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.